Instrument Inactif

Autres langues Savara Inc Nyse

Actions

US5763141083

Cours en clôture Nyse Autres places de cotation
- ^USD	-

28/06	Savara fixe le prix de son offre d'actions ordinaires à 100 millions de dollars	MT
26/06	Mise à jour sectorielle : Les actions du secteur de la santé mélangées avant la cloche mercredi	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock	01/07
Savara Prices $100 Million Common Shares Offering	28/06
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock	28/06
Savara Announces Molgramostim Nebulizer Solution Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial	27/06
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	26/06
Sector Update: Health Care	26/06
Savara's Phase 3 Trial for Molgramostim Nebulizer Solution Meets Primary Endpoint; Shares Rise Pre-Bell	26/06
Savara's rare lung disease drug meets main goal in late-stage study	26/06
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	26/06
Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial	26/06
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	26/06
Savara Inc.(NasdaqGS:SVRA) added to S&P Biotechnology Select Industry Index	24/06
Savara to Present at the Jefferies Global Healthcare Conference	29/05
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	20/05
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	19/05
Savara Announces New Employment Inducement Grant	16/05
Savara Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Savara to Present at the Citizens JMP Life Sciences Conference	07/05
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	12/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Savara Inc Nyse

Actions

US5763141083

Autres langues

Filtres